The Life Sciences Tools Re-Rating: Why Merck KGaA's $11.3 Billion Bid Just Reset a Sub-Sector the Public Market Wrote Off

John Grey — Healthcare & longevity desk

For most of the last two years, life sciences tools was the sub-sector pharma analysts apologised for owning. Funding for early-stage biotech had collapsed, academic research budgets were under pressure from the National Institutes of Health, China demand never recovered to 2021 levels, and every quarter Bio-Techne, Repligen, Danaher and Thermo Fisher reported the same story: bioprocessing volumes flat, research reagents soft, instrument orders pushed to next quarter. The Nasdaq Biotech Index had de-rated; the tools sub-index had de-rated more. By early June, Bio-Techne traded below $59, well off its 2021 high above $115, and the consensus view among generalist investors was that this was a structurally cheaper sector now — not a coiled spring.

On Wednesday morning in Darmstadt, Merck KGaA disagreed with that consensus by writing a $11.3 billion cheque. The German healthcare and chemicals conglomerate agreed to acquire Minneapolis-based Bio-Techne for $73 per share in cash — a 24% premium to the prior close and a 36% premium to the one-month volume-weighted average — making it the largest deal of Merck KGaA's history and the third multi-billion-dollar healthcare transaction announced inside seven trading days. The contrarian read is not that pharma M&A is hot. Everyone already knows pharma M&A is hot. The contrarian read is what was bought, and what that price implies about how strategics now value the unglamorous picks-and-shovels infrastructure of drug discovery.

A sub-sector the public market wrote off

The numbers behind the deal are worth pausing on. Bio-Techne generated roughly $1.2 billion in trailing twelve-month revenue at high-50s gross margins, with a portfolio spanning proteins, antibodies, cell and gene therapy workflow tools, and the ProteinSimple Western blot franchise. Merck KGaA is paying just under 10x sales and roughly 30x forward EBITDA for an asset that, two years ago, would have commanded closer to 14-16x sales when life sciences tools last traded at peak multiples. Kai Beckmann, chairman of the executive board and group CEO of Merck KGaA, made the timing logic explicit on a call with reporters following the announcement.

"We have to look into valuations, and here of course timing matters," Beckmann told Reuters, adding that a transaction at this price "wasn't possible two years ago."

Translation: the strategic buyer now believes the sub-sector has bottomed, and that paying 10x sales for a quality compounder is cheaper than building the same capability internally over five years. Merck KGaA guided to roughly EUR 140 million in run-rate synergies by year three, principally through commercial overlap with its existing MilliporeSigma research solutions business and bioprocessing footprint. The deal is structured to be modestly accretive to adjusted EPS by 2028 and the company committed to maintaining its investment-grade rating, signalling that the bid is being financed with a mix of cash on hand and new term debt at what remain attractive corporate spreads.

Sell-side reaction was unusually warm for a deal of this size. Puneet Souda, the Leerink analyst who has covered Bio-Techne since 2019, called the target an "attractive asset with strong long-term potential, despite current pressures in the research tools market" in a note to clients on the day of the announcement. Kyle Boucher at TD Cowen had upgraded Bio-Techne to Buy with a $65 price target two days earlier, flagging the name as his "top 2026 small/mid-cap idea" — a recommendation that aged spectacularly within forty-eight hours.

The deal nobody priced

What makes this transaction the cleanest signal of the cycle is the context around it. Pharma and life sciences M&A is having a year that veterans of the sector describe as comparable only to 2020. According to deal data tracked by EY, year-to-date pharma M&A value crossed $134 billion by mid-June, with the first quarter alone clocking roughly $65 billion — the strongest opening three months since the immediate post-pandemic rush. That is the macro frame; the micro frame is the cadence. In a fortnight, the market has digested Sun Pharma's $11.75 billion bid for Organon (early April closed values), GSK's $10.6 billion all-cash deal for oncology specialist Nuvalent (early June), AbbVie's $10.9 billion takeout of Apogee Therapeutics (June 22), and now Merck KGaA paying $11.3 billion for a tools platform. Four deals, four different sub-sectors — generics, oncology biotech, inflammation biologics, and now research infrastructure — all clearing above $10 billion in cash within ten weeks.

Speaking at the BIO International Convention in San Diego the same day, Anamaria Sudarov, managing director and head of healthcare investment banking at Wells Fargo, described the operating environment to the assembled biotech executives in unusually plain language.

"$65 billion year-to-date M&A swamp has meant a lot of investors with a significant amount of capital to redeploy, and they are eager to do that," Sudarov said. She noted that dual-track processes — running an IPO and a sale in parallel — have become "the bare minimum" for any late-stage private asset, with companies "filing for an IPO on Friday, and then Monday you see the announcement in M&A."

Sudarov's read explains a structural feature of this cycle that the M&A league tables miss. The buyers are not just big pharma chasing patent-cliff exposure. The buyers are also European specialty conglomerates like Merck KGaA, Asian acquirers like Sun Pharma, and private equity sponsors recycling capital from earlier therapeutics flips into platform assets. The capital base bidding for healthcare is wider than at any point since 2015, and it is bidding at a moment when public-market valuations across biotech and tools are still 30-40% below their 2021 highs. The arithmetic of strategic patience has flipped.

What the board was actually approving

The Bio-Techne board's approval document is also worth reading carefully. Robert V. Baumgartner, the company's chairman, said in the announcement release that the directors' "thorough review led the board to conclude the deal delivered substantial, near-term value" for shareholders — a phrasing that translates from corporate disclosure into the admission that the standalone plan, however good the long-term thesis, was not going to deliver $73 within any reasonable shareholder horizon. The board chose certainty over optionality, and they did so at a multiple that arguably under-pays for the cell and gene therapy reagents franchise, which is the fastest-growing segment of the tools market and the one Merck KGaA most explicitly wanted.

The market reaction confirmed the asymmetry. Bio-Techne closed up 21% on the announcement; competitor Repligen rose 4%, Danaher 1.5%, and the Vaneck Biotech ETF was flat. In other words, the bid was a Bio-Techne-specific event rather than a sector re-rating — for now. The interesting question is whether that holds. If Merck KGaA at 10x sales sets a floor under tools multiples, the next strategic that wants to buy in is going to pay closer to 12x. Repligen, MaxCyte, and the bioprocessing units of Sartorius and Thermo Fisher's cell therapy franchises are all conversations being had in conference rooms this week that were not being had a month ago.

Our view

The market has spent two years treating life sciences tools as a structurally impaired sub-sector because biotech funding was weak and China demand never recovered. Merck KGaA's $11.3 billion bid is not a contrarian call on tools — it is an admission by a strategic with privileged information about its own customer base that the cyclical bottom is behind us and the unit economics still work at scale. The takeaway for portfolio managers is narrower than the deal release suggests: this is not a green light to chase the biotech ETF complex, where IPO supply will resume aggressively into any rally. It is a green light to look at the picks-and-shovels names that have been left for dead — bioprocessing, reagents, cell and gene therapy workflow — and to assume that the multiple compression is more advanced than the operating fundamentals warrant. Pair-trade the strongest balance sheets in the sub-sector against the broader biotech tape and the asymmetry sits in your favour. Watch Repligen and MaxCyte for follow-on bids. And watch Merck KGaA's leverage ratio — investment-grade discipline is the constraint that determines whether this is the last big tools deal of the cycle or the first of several.

Solomon Grey Capital research notes are for informational purposes only and do not constitute investment advice. The authors and affiliated entities may hold positions in securities mentioned. Quotations from named sources are sourced from publicly available reporting cited in context and have been independently verified at the time of writing.